Clinical and molecular correlates in fragile X premutation females

Poonnada Jiraanont, Stefan R. Sweha, Reem R. AlOlaby, Marisol Silva, Hiu Tung Tang, Blythe Durbin-Johnson, Andrea Schneider, Glenda M. Espinal, Paul J Hagerman, Susan M. Rivera, David R Hessl, Randi J Hagerman, Nuanchan Chutabhakdikul, Flora Tassone

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The prevalence of the fragile X premutation (55–200 CGG repeats) among the general population is relatively high, but there remains a lack of clear understanding of the links between molecular biomarkers and clinical outcomes. In this study we investigated the correlations between molecular measures (CGG repeat size, FMR1 mRNA, FMRP expression levels, and methylation status at the promoter region and in FREE2 site) and clinical phenotypes (anxiety, obsessive compulsive symptoms, depression and executive function deficits) in 36 adult premutation female carriers and compared to 24 normal control subjects. Premutation carriers reported higher levels of obsessive compulsive symptoms, depression, and anxiety, but demonstrated no significant deficits in global cognitive functions or executive function compared to the control group. Increased age in carriers was significantly associated with increased anxiety levels. As expected, FMR1 mRNA expression was significantly correlated with CGG repeat number. However, no significant correlations were observed between molecular (including epigenetic) measures and clinical phenotypes in this sample. Our study, albeit limited by the sample size, establishes the complexity of the mechanisms that link the FMR1 locus to the clinical phenotypes commonly observed in female carriers suggesting that other factors, including environment or additional genetic changes, may have an impact on the clinical phenotypes. However, it continues to emphasize the need for assessment and treatment of psychiatric problems in female premutation carriers.

Original languageEnglish (US)
Pages (from-to)49-56
Number of pages8
JournaleNeurologicalSci
Volume7
DOIs
StatePublished - Jun 1 2017

Fingerprint

Phenotype
Anxiety
Executive Function
Depression
Messenger RNA
Needs Assessment
Genetic Promoter Regions
Epigenomics
Sample Size
Cognition
Methylation
Psychiatry
Biomarkers
Control Groups
Population

Keywords

  • Executive function
  • FREE2 methylation
  • Premutation alleles
  • Psychiatric problems

ASJC Scopus subject areas

  • Neurology

Cite this

Jiraanont, P., Sweha, S. R., AlOlaby, R. R., Silva, M., Tang, H. T., Durbin-Johnson, B., ... Tassone, F. (2017). Clinical and molecular correlates in fragile X premutation females. eNeurologicalSci, 7, 49-56. https://doi.org/10.1016/j.ensci.2017.04.003

Clinical and molecular correlates in fragile X premutation females. / Jiraanont, Poonnada; Sweha, Stefan R.; AlOlaby, Reem R.; Silva, Marisol; Tang, Hiu Tung; Durbin-Johnson, Blythe; Schneider, Andrea; Espinal, Glenda M.; Hagerman, Paul J; Rivera, Susan M.; Hessl, David R; Hagerman, Randi J; Chutabhakdikul, Nuanchan; Tassone, Flora.

In: eNeurologicalSci, Vol. 7, 01.06.2017, p. 49-56.

Research output: Contribution to journalArticle

Jiraanont, P, Sweha, SR, AlOlaby, RR, Silva, M, Tang, HT, Durbin-Johnson, B, Schneider, A, Espinal, GM, Hagerman, PJ, Rivera, SM, Hessl, DR, Hagerman, RJ, Chutabhakdikul, N & Tassone, F 2017, 'Clinical and molecular correlates in fragile X premutation females', eNeurologicalSci, vol. 7, pp. 49-56. https://doi.org/10.1016/j.ensci.2017.04.003
Jiraanont P, Sweha SR, AlOlaby RR, Silva M, Tang HT, Durbin-Johnson B et al. Clinical and molecular correlates in fragile X premutation females. eNeurologicalSci. 2017 Jun 1;7:49-56. https://doi.org/10.1016/j.ensci.2017.04.003
Jiraanont, Poonnada ; Sweha, Stefan R. ; AlOlaby, Reem R. ; Silva, Marisol ; Tang, Hiu Tung ; Durbin-Johnson, Blythe ; Schneider, Andrea ; Espinal, Glenda M. ; Hagerman, Paul J ; Rivera, Susan M. ; Hessl, David R ; Hagerman, Randi J ; Chutabhakdikul, Nuanchan ; Tassone, Flora. / Clinical and molecular correlates in fragile X premutation females. In: eNeurologicalSci. 2017 ; Vol. 7. pp. 49-56.
@article{c65a6fa4a5bb4f7c99743da2e3c2c19f,
title = "Clinical and molecular correlates in fragile X premutation females",
abstract = "The prevalence of the fragile X premutation (55–200 CGG repeats) among the general population is relatively high, but there remains a lack of clear understanding of the links between molecular biomarkers and clinical outcomes. In this study we investigated the correlations between molecular measures (CGG repeat size, FMR1 mRNA, FMRP expression levels, and methylation status at the promoter region and in FREE2 site) and clinical phenotypes (anxiety, obsessive compulsive symptoms, depression and executive function deficits) in 36 adult premutation female carriers and compared to 24 normal control subjects. Premutation carriers reported higher levels of obsessive compulsive symptoms, depression, and anxiety, but demonstrated no significant deficits in global cognitive functions or executive function compared to the control group. Increased age in carriers was significantly associated with increased anxiety levels. As expected, FMR1 mRNA expression was significantly correlated with CGG repeat number. However, no significant correlations were observed between molecular (including epigenetic) measures and clinical phenotypes in this sample. Our study, albeit limited by the sample size, establishes the complexity of the mechanisms that link the FMR1 locus to the clinical phenotypes commonly observed in female carriers suggesting that other factors, including environment or additional genetic changes, may have an impact on the clinical phenotypes. However, it continues to emphasize the need for assessment and treatment of psychiatric problems in female premutation carriers.",
keywords = "Executive function, FREE2 methylation, Premutation alleles, Psychiatric problems",
author = "Poonnada Jiraanont and Sweha, {Stefan R.} and AlOlaby, {Reem R.} and Marisol Silva and Tang, {Hiu Tung} and Blythe Durbin-Johnson and Andrea Schneider and Espinal, {Glenda M.} and Hagerman, {Paul J} and Rivera, {Susan M.} and Hessl, {David R} and Hagerman, {Randi J} and Nuanchan Chutabhakdikul and Flora Tassone",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.ensci.2017.04.003",
language = "English (US)",
volume = "7",
pages = "49--56",
journal = "eNeurologicalSci",
issn = "2405-6502",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Clinical and molecular correlates in fragile X premutation females

AU - Jiraanont, Poonnada

AU - Sweha, Stefan R.

AU - AlOlaby, Reem R.

AU - Silva, Marisol

AU - Tang, Hiu Tung

AU - Durbin-Johnson, Blythe

AU - Schneider, Andrea

AU - Espinal, Glenda M.

AU - Hagerman, Paul J

AU - Rivera, Susan M.

AU - Hessl, David R

AU - Hagerman, Randi J

AU - Chutabhakdikul, Nuanchan

AU - Tassone, Flora

PY - 2017/6/1

Y1 - 2017/6/1

N2 - The prevalence of the fragile X premutation (55–200 CGG repeats) among the general population is relatively high, but there remains a lack of clear understanding of the links between molecular biomarkers and clinical outcomes. In this study we investigated the correlations between molecular measures (CGG repeat size, FMR1 mRNA, FMRP expression levels, and methylation status at the promoter region and in FREE2 site) and clinical phenotypes (anxiety, obsessive compulsive symptoms, depression and executive function deficits) in 36 adult premutation female carriers and compared to 24 normal control subjects. Premutation carriers reported higher levels of obsessive compulsive symptoms, depression, and anxiety, but demonstrated no significant deficits in global cognitive functions or executive function compared to the control group. Increased age in carriers was significantly associated with increased anxiety levels. As expected, FMR1 mRNA expression was significantly correlated with CGG repeat number. However, no significant correlations were observed between molecular (including epigenetic) measures and clinical phenotypes in this sample. Our study, albeit limited by the sample size, establishes the complexity of the mechanisms that link the FMR1 locus to the clinical phenotypes commonly observed in female carriers suggesting that other factors, including environment or additional genetic changes, may have an impact on the clinical phenotypes. However, it continues to emphasize the need for assessment and treatment of psychiatric problems in female premutation carriers.

AB - The prevalence of the fragile X premutation (55–200 CGG repeats) among the general population is relatively high, but there remains a lack of clear understanding of the links between molecular biomarkers and clinical outcomes. In this study we investigated the correlations between molecular measures (CGG repeat size, FMR1 mRNA, FMRP expression levels, and methylation status at the promoter region and in FREE2 site) and clinical phenotypes (anxiety, obsessive compulsive symptoms, depression and executive function deficits) in 36 adult premutation female carriers and compared to 24 normal control subjects. Premutation carriers reported higher levels of obsessive compulsive symptoms, depression, and anxiety, but demonstrated no significant deficits in global cognitive functions or executive function compared to the control group. Increased age in carriers was significantly associated with increased anxiety levels. As expected, FMR1 mRNA expression was significantly correlated with CGG repeat number. However, no significant correlations were observed between molecular (including epigenetic) measures and clinical phenotypes in this sample. Our study, albeit limited by the sample size, establishes the complexity of the mechanisms that link the FMR1 locus to the clinical phenotypes commonly observed in female carriers suggesting that other factors, including environment or additional genetic changes, may have an impact on the clinical phenotypes. However, it continues to emphasize the need for assessment and treatment of psychiatric problems in female premutation carriers.

KW - Executive function

KW - FREE2 methylation

KW - Premutation alleles

KW - Psychiatric problems

UR - http://www.scopus.com/inward/record.url?scp=85020027970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020027970&partnerID=8YFLogxK

U2 - 10.1016/j.ensci.2017.04.003

DO - 10.1016/j.ensci.2017.04.003

M3 - Article

AN - SCOPUS:85020027970

VL - 7

SP - 49

EP - 56

JO - eNeurologicalSci

JF - eNeurologicalSci

SN - 2405-6502

ER -